Results 71 to 80 of about 25,523 (241)

Post‐translational regulation of human D‐3‐phosphoglycerate dehydrogenase in Alzheimer's disease

Protein Science, Volume 35, Issue 3, March 2026.
Abstract Emerging evidence suggests that sex‐specific differences in L‐serine (L‐Ser) metabolism play a key role in Alzheimer's disease (AD). While disruptions in amino acid balance are well known, recent findings point to a dimorphic regulation of the serine biosynthetic pathway.
Elena Zerbini, Daniele Riva, Elisa Maffioli, Gabriella Tedeschi, Silvia Sacchi, Loredano Pollegioni   +5 more
wiley   +1 more source

Beyond diabetes and obesity: GLP‐1 receptor agonists in disrupting the vicious cycle of metabolic dysfunction and neuroinflammation

Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 1622-1637, March 2026.
Abstract Neurodegenerative diseases, including debilitating conditions like Alzheimer's and Parkinson's, are characterized by progressive neuronal loss, a process fundamentally driven by persistent chronic neuroinflammation and central metabolic dysfunction.
Renata Spezani, Carlos A. Mandarim‐de‐Lacerda   +1 more
wiley   +1 more source

PF-06447475 Molecule Attenuates the Neuropathology of Familial Alzheimer’s and Coexistent Parkinson’s Disease Markers in PSEN1 I416T Dopaminergic-like Neurons

Molecules
Familial Alzheimer’s disease (FAD) is a complex multifactorial disorder clinically characterized by cognitive impairment and memory loss. Pathologically, FAD is characterized by intracellular accumulation of the protein fragment Aβ42 (iAβ ...
Diana Alejandra Quintero-Espinosa, Carlos Velez-Pardo, Marlene Jimenez-Del-Rio   +2 more
doaj   +1 more source

18F-FDG-PET in Mouse Models of Alzheimer's Disease

Frontiers in Medicine, 2019
Suitable animal models and in vivo biomarkers are essential for development and evaluation of new therapeutic strategies in Alzheimer's disease (AD). 18F-Fluorodeoxyglucose (18F-FDG)-positron-emission tomography (PET) is an imaging biomarker that allows ...
Caroline Bouter, Yvonne Bouter
doaj   +1 more source

Metformin Impairs Breast Cancer Growth through the Inhibition of PRMT6

Advanced Science, Volume 13, Issue 8, 9 February 2026.
Metformin has a biological activity against breast cancer. However, it is largely unknown about its precise therapeutic targets. Here, histone arginine methyltransferase PRMT6 is identified as a new anti‐cancer target for metformin. Metformin directly binds PRMT6 and inhibits its ability to catalyze histone H3R2 asymmetric dimethylation (H3R2me2a ...
Yinsheng Wu, Xinlin Xu, Yue Tong, Min Wang, Feng Ge, Min Wu, Yunlong Wang, Gang Chen, Xilan Yu, Shanshan Li   +9 more
wiley   +1 more source

Increased mitochondrial calcium uptake and concomitant mitochondrial activity by presenilin loss promotes mTORC1 signaling to drive neurodegeneration [PDF]

, 2021
Kerry C. Ryan, Zahra Ashkavand, Shaarika Sarasija, Jocelyn T. Laboy, Rohan Samarakoon, Kenneth R. Norman   +5 more
openalex   +1 more source

Making the final cut: pathogenic amyloid-β peptide generation by γ-secretase

Cell Stress, 2018
Alzheimer´s disease (AD) is a devastating neurodegenerative disease of the elderly population. Genetic evidence strongly suggests that aberrant generation and/or clearance of the neurotoxic amyloid-β peptide (Aβ) is triggering the disease.
Harald Steiner, Akio Fukumori, Shinji Tagami, Masayasu Okochi   +3 more
doaj   +1 more source

Relationship between age and severity of cognitive impairment at diagnosis for early‐onset and late‐onset Alzheimer's disease: Comparison of LEADS and ADNI

Alzheimer's &Dementia, Volume 22, Issue 2, February 2026.
INTRODUCTION Recent work has identified unique cognitive profiles for early‐onset Alzheimer's disease (EOAD) relative to late‐onset Alzheimer's disease (LOAD), however, examination has been limited in determining whether the association between age and cognitive severity at presentation also differs across conditions.
Dustin B. Hammers, Ani Eloyan, Maryanne Thangarajah, Alexander Taurone, Sujuan Gao, Laurel Beckett, Kala Kirby, Jeffrey L. Dage, Kelly Nudelman, Paul Aisen, Rema Reman, Prashanthi Vemuri, Renaud La Joie, Alexandra Touroutoglou, Alireza Atri, David Clark, Gregory S. Day, Ranjan Duara, Neill R. Graff‐Radford, Lawrence S. Honig, David T. Jones, Joseph C. Masdeu, Mario F. Mendez, Kyle Womack, Erik Musiek, Chiadi U. Onyike, Meghan Riddle, Ian Grant, Emily Rogalski, Erik C. B. Johnson, Steven Salloway, Sharon J. Sha, Raymond Scott Turner, Thomas S. Wingo, David A. Wolk, Maria C. Carrillo, Bradford C. Dickerson, Gil D. Rabinovici, Liana G. Apostolova, LEADS Consortium, for the Alzheimer's Disease Neuroimaging Initiative   +40 more
wiley   +1 more source

RBFOX1 association with age at onset of Alzheimer's disease

Alzheimer's &Dementia, Volume 22, Issue 2, February 2026.
Abstract INTRODUCTION Genetic contributors to early onset Alzheimer's disease (AD) beyond APP and PSEN1/2 remain unknown. Identifying novel loci may reveal disease mechanisms and therapeutic targets. We investigated genetic variants influencing age at onset in early onset families from the Long‐Life Family Study (LLFS).
Laura Xicota, Rong Cheng, Stacy L. Andersen, Joseph M. Zmuda, Mary Wojczynski, Mary F. Feitosa, Joseph Bradley, Carlos Cruchaga, Alex G. Contreras, Timothy J. Hohman, Dolly Reyes‐Dumeyer, Badri V. Vardarajan, Stephanie Cosentino, Richard Mayeux, Joseph H. Lee, Sandra Barral, the Long‐Life Family Study (LLFS), Estudio Familiar de Influencia Genetica en Alzheimer (EFIGA), and The National Institute on Aging Alzheimer's Disease Family Based Study (NIA‐LOAD FBS)   +18 more
wiley   +1 more source

Correction: γ‑Secretase modulator resistance of an aggressive Alzheimer‑causing presenilin mutant can be overcome in the heterozygous patient state by a set of advanced compounds. [PDF]

Alzheimers Res Ther
Trambauer J, Sarmiento RMR, Garringer HJ, Salbaum K, Pedro LD, Crusius D, Vidal R, Ghetti B, Paquet D, Baumann K, Lindemann L, Steiner H.   +11 more
europepmc   +3 more sources